Fu Y, et al. - Via this retrospective analysis of non-small cell lung cancer (NSCLC) patients with chronic hepatitis B viral (HBV) infection, researchers examined the link between pretreatment serum HBV DNA copy numbers and clinical outcome in these cases. This study included 188 patients with a median age of 56 years and median overall survival (OS) of 34 months. Using four prognostic factors, a nomogram model for survival was developed. For HBV DNA, TNM stage, and for the nomogram model, the estimated concordance index (C-index) was 0.67, 0.69, and 0.76, respectively. Compared to HBV DNA and TNM stage, statistically higher C-index values of nomogram model were evident. They concluded that in NSCLC patients with chronic HBV infection, pretreatment serum HBV DNA copy numbers can serve as a prognostic marker of survival.